The Menopause Drug Market Just Split in Two and the Capital Opportunity Is Bigger Than Either Drug
Why inconsistent AI diagnoses aren’t a breakthrough, but a signal that both medicine and machine learning are built on incomplete data and what that means for investors
📕Special note: My book The Billion Dollar Blindspot is available for pre-order on Amazon. It’s currently #3 on Amazon hot new releases in our category. Will you help me make it to #1?
PwC just sized the women's health market at $600 billion by 2030. That number includes a midlife biology gap that serious allocators are now starting to move toward.
GLP-1 drugs have trained institutional capital to believe that treating the underlying biology of aging generates extraordinary returns. What that capital is only beginning to find is that women’s midlife biology is the single largest uncaptured frontier in that thesis. Two regulatory decisions this month just made that frontier considerably more visible.
In the US, the FDA approved Bayer’s elinzanetant — brand name Lynkuet — as the first dual NK1 and NK3 receptor antagonist for moderate to severe menopausal hot flashes.
In the UK, NICE issued final draft guidance recommending Veoza (fezolinetant, Astellas) for NHS prescribing — the first drug in this class backed for state-funded use, reaching an estimated 500,000 women in England who cannot take HRT.
What happened
Two different drugs, two different mechanisms within the same neurological pathway, cleared by two of the world’s most scrutinised regulatory systems within weeks of each other. Lynkuet targets both NK1 and NK3 receptors. Veoza targets NK3 alone. Both treat vasomotor symptoms by modulating the thermoregulatory pathway directly, without hormones. NICE — an agency that rejects drugs on cost-effectiveness grounds more often than it approves them — backed Veoza specifically for women contraindicated for HRT due to breast cancer, clotting disorders, or cardiovascular history.
Why it matters
One approval is a scientific milestone. Two approvals across the FDA and NICE is a validated market. The neurokinin pathway is no longer a speculative mechanism — it is a proven, reimbursable treatment category for one of the most prevalent and undertreated conditions in women’s health.
Seventy percent of menopausal women experience vasomotor symptoms. In the US alone, only 2 million of 41 million eligible women currently receive any treatment.
The HRT black box removal opens that suppressed demand from one direction. Non-hormonal approvals open it from another — for a clinically distinct population with different contraindication profiles, different prescribing pathways, and critically different payer dynamics.
These are not competing markets. They are additive. NICE just proved that a major public payer will fund this category. That signal travels well beyond the UK.
What this signals for investors
Here is where the capital opportunity gets interesting. I have watched pharmaceutical categories validate like this before and the pattern that follows is consistent. The first approval proves the science. The second proves the market. What comes immediately after is a fast-follower wave and a reimbursement race that reshapes the entire adjacent stack.
The question worth asking now is not which drug wins — it is what a validated, reimbursable, non-hormonal menopause category does to every company already positioned next to it.
Telehealth platforms prescribing menopause care just gained a new product line with a reimbursement pathway.
Digital therapeutics targeting symptom management now sit in a more competitive but also more legitimate market.
Any company building toward NHS or payer partnerships in menopause — Midi Health, Stella, Peppy, Issviva — just had their reimbursement thesis de-risked by a NICE decision that proves payers will pay.
We are also in an environment where US public research funding is contracting and private capital is the only engine with both the speed and the incentive to build what comes next in this category. The companies that move now — that use this validation window to build clinical evidence, payer relationships, and distribution before the fast-follower wave arrives — will not exit at consumer health multiples. They will exit at pharmaceutical infrastructure multiples. That gap is one of the more compelling setups in women’s health right now.
If you are a healthcare angel investor or capital allocator, this briefing is written for you. Join the capital briefing. Written by a 25-year veteran in global financial markets.
Three years ago, I started writing what I thought was a report. It became a book. Today, The Billion Dollar Blindspot is available for pre-order. But this didn’t start as a book. It started in a gynecologist’s office; confused, dismissed, and aware that something wasn’t adding up, not just medically but structurally.
Sources
FDA approval announcement, Lynkuet (elinzanetant): https://www.fda.gov/news-events/press-announcements/hhs-advances-womens-health-removes-misleading-fda-warnings-hormone-replacement-therapy
NICE final draft guidance, fezolinetant (Veoza): https://www.nice.org.uk/guidance/indevelopment/gid-ta11058
NICE supports NHS prescribing of fezolinetant — Women’s Health Concern: https://www.womens-health-concern.org/2026/03/nice-supports-nhs-prescribing-of-fezolinetant/
WEF Women’s Health Investment Outlook 2026: https://www.weforum.org/publications/women-s-health-investment-outlook-2026/
PwC, From Margin to Mainstream: The Future of Women's Health (March 2026): https://www.pwc.com/us/en/industries/health-industries/library/the-future-of-womens-health.html
Disclaimer & Disclosure
This content is for informational and educational purposes only. It does not constitute financial, investment, legal, or medical advice, or an offer to buy or sell any securities. Opinions expressed are those of the author and may not reflect the views of affiliated organisations. Readers should seek professional advice tailored to their individual circumstances before making investment decisions. Investing involves risk, including potential loss of principal. Past performance does not guarantee future results.